‘Leerink Swann Research analyst Joseph P. Schwartz reaffirmed a "Outperform" rating for Human Genome, saying he expects Benlysta to gain regulatory approval and then reach the market by the second half of 2010. He boosted his fair value outlook for the stock to $40 from $30. He expects the company to present full results from Bliss-76 in the spring of 2010 at a medical conference.’

http://finance.yahoo.com/news/Human-Geno...

HGSI is still losing money - showing a loss over the last three years of around three-quarters of a billion dollars. The drug which has provided the excuse for all this action isn't a patch on Iplex with regard to potential revenue.

HGSI reached a low of 45 cents in March - and a high of $26.21 today.

The current price level of INSM is simply the product of a market scam - how else could they persuade suckers to sell shares for 70 cents in a company with cash alone worth 95 cents in a liquidation - and almost certain to report positive earnings in four days?